[go: up one dir, main page]

GB9925559D0 - Novel method - Google Patents

Novel method

Info

Publication number
GB9925559D0
GB9925559D0 GBGB9925559.8A GB9925559A GB9925559D0 GB 9925559 D0 GB9925559 D0 GB 9925559D0 GB 9925559 A GB9925559 A GB 9925559A GB 9925559 D0 GB9925559 D0 GB 9925559D0
Authority
GB
United Kingdom
Prior art keywords
novel method
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9925559.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Priority to GBGB9925559.8A priority Critical patent/GB9925559D0/en
Publication of GB9925559D0 publication Critical patent/GB9925559D0/en
Priority to JP2001532807A priority patent/JP2003512440A/en
Priority to PCT/EP2000/010733 priority patent/WO2001030390A2/en
Priority to EP00981226A priority patent/EP1223987A2/en
Priority to CA002388995A priority patent/CA2388995A1/en
Priority to AU18549/01A priority patent/AU1854901A/en
Priority to US10/818,819 priority patent/US20040191834A1/en
Ceased legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
GBGB9925559.8A 1999-10-28 1999-10-28 Novel method Ceased GB9925559D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB9925559.8A GB9925559D0 (en) 1999-10-28 1999-10-28 Novel method
JP2001532807A JP2003512440A (en) 1999-10-28 2000-10-27 New method
PCT/EP2000/010733 WO2001030390A2 (en) 1999-10-28 2000-10-27 Method
EP00981226A EP1223987A2 (en) 1999-10-28 2000-10-27 Method
CA002388995A CA2388995A1 (en) 1999-10-28 2000-10-27 Method
AU18549/01A AU1854901A (en) 1999-10-28 2000-10-27 Novel method
US10/818,819 US20040191834A1 (en) 1999-10-28 2004-04-06 Novel method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9925559.8A GB9925559D0 (en) 1999-10-28 1999-10-28 Novel method

Publications (1)

Publication Number Publication Date
GB9925559D0 true GB9925559D0 (en) 1999-12-29

Family

ID=10863574

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9925559.8A Ceased GB9925559D0 (en) 1999-10-28 1999-10-28 Novel method

Country Status (6)

Country Link
EP (1) EP1223987A2 (en)
JP (1) JP2003512440A (en)
AU (1) AU1854901A (en)
CA (1) CA2388995A1 (en)
GB (1) GB9925559D0 (en)
WO (1) WO2001030390A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1449293B (en) * 2000-06-29 2012-08-22 史密丝克莱恩比彻姆生物有限公司 multivalent vaccine composition
KR100947757B1 (en) 2001-01-23 2010-03-18 아벤티스 파스퇴르 Multivalent Meningococcal Polysaccharide-Protein Conjugate Vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
EP1549338B1 (en) 2002-10-11 2010-12-22 Novartis Vaccines and Diagnostics S.r.l. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
ES2383175T3 (en) 2003-01-30 2012-06-18 Novartis Ag Injectable vaccines against multiple serogroups of meningococci
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
PL1670506T3 (en) 2003-10-02 2013-04-30 Novartis Ag Liquid vaccines for multiple meningococcal serogroups
BRPI0417689A8 (en) 2003-12-17 2017-04-25 Elan Pharm Inc METHOD FOR CONJUGATING A PEPTIDE IMMOGEN, COMPOSITION, CONJUGATE, IMMUNOGENIC COMPOSITION, METHOD FOR INDUCING AN IMMUNE RESPONSE IN A MAMMAL INDIVIDUAL, AND, USE OF THE CONJUGATE
BRPI0612655B1 (en) 2005-06-27 2021-06-15 Pfizer Ireland Pharmaceuticals IMMUNOGENIC COMPOSITION
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
PL2004225T3 (en) 2006-03-22 2012-09-28 Novartis Ag Regimens for immunisation with meningococcal conjugates
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
US8956625B2 (en) 2006-09-07 2015-02-17 Glaxosmithkline Biologicals, S.A. Inactivated polio vaccines
JP2010525035A (en) 2007-05-02 2010-07-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム vaccine
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
BR122016015627A2 (en) 2007-10-19 2018-10-30 Novartis Ag kit, lyophilized antigen composition and method for preparation of an immunogenic composition
CA2716212A1 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
WO2010070453A2 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
CN102438649A (en) 2009-03-24 2012-05-02 诺华有限公司 Meningococcal factor H binding proteins and pneumococcal binding saccharides
EP3017828A1 (en) 2009-08-27 2016-05-11 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
EP2483390A2 (en) 2009-09-30 2012-08-08 Novartis AG Expression of meningococcal fhbp polypeptides
CN102917730A (en) 2009-10-27 2013-02-06 诺华有限公司 Modified meningococcal fHBP polypeptides
AU2011300418B2 (en) 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
WO2012153302A1 (en) 2011-05-12 2012-11-15 Novartis Ag Antipyretics to enhance tolerability of vesicle-based vaccines
CN102507924B (en) * 2011-11-17 2014-06-18 成都欧林生物科技股份有限公司 Method for detecting concentration of polysaccharide in zymotic fluid
ES2654613T3 (en) 2012-02-02 2018-02-14 Glaxosmithkline Biologicals Sa Promoters for increased protein expression in meningococci

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604108A (en) * 1992-09-14 1997-02-18 Connaught Laboratories, Inc. Test for determining the dose response of a conjugated vaccine
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
DE122009000054I1 (en) * 1999-03-19 2009-12-31 Glaxosmithkline Biolog Sa VACCINE AGAINST BACTERIAL ANTIGENE

Also Published As

Publication number Publication date
WO2001030390A2 (en) 2001-05-03
JP2003512440A (en) 2003-04-02
AU1854901A (en) 2001-05-08
CA2388995A1 (en) 2001-05-03
EP1223987A2 (en) 2002-07-24
WO2001030390A3 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
GB9920644D0 (en) Novel method
GB9925559D0 (en) Novel method
GB9918031D0 (en) Method
GB9916757D0 (en) Method
GB0007871D0 (en) Method
GB9915625D0 (en) Method
GB9919370D0 (en) Method
GB9918681D0 (en) Novel method
GB2355455B (en) Method
GB9904158D0 (en) Novel method
GB9911939D0 (en) Method
GB9926435D0 (en) Method
GB9915936D0 (en) Method
GB9911796D0 (en) Novel method
GB9911795D0 (en) Novel method
GB9925138D0 (en) Novel method
GB9922241D0 (en) Novel method
GB9905387D0 (en) Novel method
GB9905388D0 (en) Novel method
GB9905389D0 (en) Novel method
GB9911790D0 (en) Novel method
GB9911794D0 (en) Novel method
GB9906852D0 (en) Method
GB9916567D0 (en) Method
GB9905669D0 (en) Method

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)